Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma
Ключови думи
Резюме
Описание
Background:
ACC is an extremely rare disease. About 30% of patients are diagnosed with locally/advanced metastatic disease and about 50-80% of patients who undergo radical resection are destined to relapse often with distant metastases. Approximately 50% of ACC in adults are functioning leading to hormonal and metabolic syndromes. Cortisol hypersecretion (Cushing's syndrome) is the most common endocrine derangement at presentation. Control of the syndrome is mainly obtained by mitotane therapy, however this drug requires several weeks to months for attaining a therapeutic range of serum concentrations. Hypercortisolism is one of the factors that negatively influence the outcome of patients with metastatic ACC.
Abiraterone acetate (AA) is a prodrug of abiraterone, an irreversible inhibitor of 17α hydroxylase/C17, 20-lyase (cytochrome P450c17 [CYP17]), that are key enzymes required for testosterone synthesis. These enzymes are found in the testes, adrenals and prostate tumors. The inhibition of CYP17A1 blocks androgen and cortisol synthesis. Abiraterone has demonstrated to be able to suppress dehydroepiandrosterone (DHEA), androstenedione and testosterone production in both adrenal and testes and to reduce adrenal cortisol production. For these reasons Abiraterone is registered for clinical use in castrate-resistant prostate cancer (CRPC). The maximum inhibition of CYP17A1 is achieved within 28 days of continuous dosing.
Rationale:
- A rapid control of the Cushing's syndrome is important in patients with ACC.
- AA has a pharmacodynamic potential to reduce cortisol excess and it has never been tested before in Cushing's syndrome.
Statistical considerations:
The sample size in Cohort 1 according to an Intent To Treat (ITT) procedure is calculated under the following considerations:
H0: current therapies can normalize UFC in 40% of patients in 1 month of therapy; H1: Abiraterone can normalize UFC in at least 70% of patients in 1 month of therapy.
Therefore, the sample size calculation is based on the comparison between the response observed with traditional therapies (R0 = 0.4) and the response expected with the experimental drug (R1 = 0.7). With a two-sided Chi-square test, twenty consecutive patients should be enrolled to detect a 30% absolute difference with an alpha error 5% and a power of 80%.
Considering the exploratory purpose of Cohort 2 substudy, no sample size has been determined and a total of 10 patients will be enrolled.
Abiraterone administration and dose modifications:
Abiraterone Acetate will be administered per os at the standard dose of four 250 mg capsules (1000 mg total dose) daily on an empty stomach in 28-day cycles.
In case of an adverse event (AE) where according to investigator judgement a dose-reduction is required, 1 dose reduction is allowed to 500 mg Abiraterone (4→2 tablets). Any return to protocol dose level (4 tablets) after dose reduction must follow documentation of adverse event resolution.
Safety and management of AEs:
The evaluation period for safety will start from signing of the informed consent form to at least 30 days after the last dose of study drug or recovery from all acute toxicities associated with study drug administration. Adverse events including laboratory AEs will be graded and summarized according to the NCI-CTCAE, Version 4.0. The study will include evaluations of safety according to the time points provided in the Time and Events Schedule.
Дати
| Последна проверка: | 04/30/2017 |
| Първо изпратено: | 04/25/2017 |
| Очаквано записване подадено: | 05/04/2017 |
| Първо публикувано: | 05/08/2017 |
| Изпратена последна актуализация: | 05/08/2017 |
| Последна актуализация публикувана: | 05/09/2017 |
| Действителна начална дата на проучването: | 04/17/2017 |
| Приблизителна дата на първично завършване: | 04/17/2020 |
| Очаквана дата на завършване на проучването: | 04/17/2021 |
Състояние или заболяване
Интервенция / лечение
Drug: Abiraterone Acetate
Фаза
Групи за ръце
| Arm | Интервенция / лечение |
|---|---|
| Experimental: Cohort 1 Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy.
Treatment with single agent Abiraterone Acetate (AA) until progression | |
| Experimental: Cohort 2 Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection.
Treatment with single agent Abiraterone Acetate (AA) for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month, then Mitotane +/- chemotherapy can be started upon the clinician's decision. |
Критерии за допустимост
| Възрасти, отговарящи на условията за проучване | 18 Years Да се 18 Years |
| Полове, допустими за проучване | All |
| Приема здрави доброволци | Да |
| Критерии | Inclusion Criteria: - Histologically-confirmed diagnosis of ACC - CT or MRI evidence of metastatic or locally advanced ACC (ENSAT stage III-IV) unsuitable for radical surgery - Age ≥ 18 years - Confirmed diagnosis of Cushing's syndrome validated by: - two 24 h urinary collections for UFC at least 1.5 times the upper the normal levels, within 2 weeks prior to enrollment; - serum ACTH levels lower than the normal range; - ECOG performance status ≤ 2 - Effective contraception - Patients must provide verbal and written informed consent to be enrolled in the study Exclusion Criteria: - Life expectancy less than 3 months - Liver disease, such as cirrhosis, chronic or persistent active hepatitis or AST/ALT > 2 x ULN, bilirubin >2 x ULN - Heart failure (NYHA class III or IV), unstable angina, severe arrhythmia or clinically significant impairment of heart function - Major surgical procedure within one month prior entering the study - Renal impairment (creatinine clearance < 40 ml/min). - WBC <3 x 109 /L; Hb <13 g/dL for men and <12 g/dL for women; platelets <100 x 109 /L - Any other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study. - Pregnant or breast-feeding women - History of alcohol or drug abuse - History of recent or active prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, or other treated malignancies with no evidence of disease for at least three years) - Acute or chronic uncontrolled infections - Patient non-compliance |
Резултат
Първични изходни мерки
1. To assess the activity of AA in attaining normalization of 24-h urinary free cortisol (UFC) excretion relative to baseline within 1 month from treatment start [1 month]
Вторични изходни мерки
1. to assess the activity of AA in attaining 50% reduction of 24-h UFC excretion within 1 month of treatment [1 month]
2. time to reduction of UFC (compared to screening values) [Weekly, from date of treatment start, for the first month; thereafter every 2 months up to 48 months.]
3. effect of AA on levels of serum cortisol, UFC, salivary cortisol, ACTH, aldosterone, PRA, DHEA-S, total testosterone, and steroid precursors [Monthly, from date of treatment start, for the first 3 months; thereafter every 2 months up to 48 months]
4. improvement of the clinical signs associated to hypercortisolism [every visit up to 48 months]
5. improvement of quality of life [every visit up to 48 months]
6. safety and tolerability of oral assumption of AA [Weekly, from date of treatment start, for the first month; once a month for the first 3 months; thereafter every 2 months up to 48 months]
7. treatment response (according to RECIST criteria) [every 3 months or earlier upon clinician's decision, up to 48 months]
8. progression-free survival [every visit up to 48 months]
9. time to syndrome relapse [every visit up to 48 months]
10. overall survival [every visit up to 48 months]
